Just a few months after a German publication reported that Bayer was prepping a top-to-bottom R&D review to see how much money — and jobs — could be squeezed out, the rumor mill has turned smoking hot again with a report from Reuters that seems to confirm the scuttlebutt.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,